Gene Expression Studies in Major Depression

Divya Mehta · Andreas Menke · Elisabeth B. Binder

Published online: 23 March 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com

Abstract The dramatic technical advances in methods to measure gene expression on a genome-wide level thus far have not been paralleled by breakthrough discoveries in psychiatric disorders—including major depression (MD)—using these hypothesis-free approaches. In this review, we first describe the methodologic advances made in gene expression analysis, from quantitative polymerase chain reaction to next-generation sequencing. We then discuss issues in gene expression experiments specific to MD, ranging from the choice of target tissues to the characterization of the case group. We provide a synopsis of the gene expression studies published thus far for MD, with a focus on studies using mRNA microarray methods. Finally, we discuss possible new strategies for the gene expression studies in MD that circumvent some of the addressed issues.

Keywords Major depression · Gene expression · mRNA · RNA-Seq

Methods of Determining Gene Expression

The initial step in gene expression is transcription (transfer) of genetic information contained in genomic DNA to mRNA. Most of the genetic regulation in humans is thought to occur at the level of gene transcription. The objective of gene expression analysis at the transcriptional level is to determine whether specific mRNA sequences transcribed from particular genes are present in cells or tissues of interest, and if so, at what level. Transcripts can be directly measured as RNA species or can be converted into cDNA via reverse transcription—a laboratory procedure that uses viral enzymes to transcribe RNA to DNA. The cDNA copies are amplified using polymerase chain reaction (PCR), and levels of transcripts within samples in a particular disease state can be compared with those in healthy samples to identify transcriptional differences between the two conditions.

Traditional methods of gene expression analysis included Northern blots, quantitative PCR (qPCR), real time qPCR,
and in situ hybridization, all of which allow profiling of the transcriptome on a limited scale restricted to single genes or small groups of genes (Fig. 1). Microarray technologies now allow parallel analysis of thousands of transcripts across many samples simultaneously. Expression levels serve as a surrogate to study the activity of a gene, even though microarrays only measure steady-state levels and do not provide information on the type of transcriptional regulation or post-transcriptional changes. Variation in transcript levels represents an intermediate stage between DNA sequence

### Methods of gene expression profiling

| Detection of specific transcripts | Global detection of transcripts |
|----------------------------------|-------------------------------|
| In situ hybridization            | RT-PCR                        |
| RNase protection assay           | Differential display PCR      |
| Northern blotting                | Microarrays                   |
| Macroarrays                      | 3'SAGE                        |
| 5'CAGE                           | 5'CAGE                        |
| MPSS                             | RNA-Seq                       |

**In situ hybridization** is a method of localizing and detecting specific mRNA sequences in morphologically preserved tissue sections or cell preparations by hybridizing labelled complementary strands of a nucleotide probe to the sequence of interest at elevated temperatures and washing away the excess probe. The labelled probe is then localized and quantified in the tissue using autoradiography, fluorescence microscopy, immunohistochemistry, or radioactivity.

**In Northern blotting**, total RNA/mRNA is size-separated by denaturing agarose gel electrophoresis, the separated RNA is transferred onto a nylon membrane, and the RNA is detected by isotopic or nonisotopic labelled probes.

**In RNase protection assays**, samples are mixed with complementary probes to form double-stranded molecules and exposed to ribonucleases that specifically cleave only single-stranded molecules. After the reaction is complete, susceptible RNA regions are degraded, and the surviving fragments retain the sequence of interest.

**In subtractive hybridization**, molecules of one mRNA pool are labelled (driver complementary DNA [cDNA]), and mRNA of another pool (tracer cDNA) are hybridized to the cDNA of the first pool, and both labelled cDNA and cDNA/mRNA hybrids are immobilized. After several rounds of hybridization and removals by streptavidin precipitation, the differentially expressed genes are left at the end.

**Reverse transcription polymerase chain reaction (RT-PCR)** is a variant of polymerase chain reaction (PCR) that is used to amplify small amounts of DNA. RNA strands are reverse transcribed into its DNA complement (cDNA) using the enzyme reverse transcriptase, amplified using traditional or real time PCR, visualized on a gel using electrophoresis, and quantified.

**Differential display PCR** is a modified form of RT-PCR that can track the expression of many genes simultaneously using partially degenerate PCR primers in which the choice of the base at some positions is intentionally flexible. The resulting amplification patterns result in a complex ladder of bands that are size-fractionated using polyacrylamide gels.

**Expression sequence tags (ESTs)** involve sequencing several hundred base pairs from ends of cDNA clones taken from a cDNA library.

**Macroarrays** are low-density arrays that preceded microarrays and are, similar to the microarrays, based on the principle of hybridization. Probes are usually printed within the pores of nylon membranes.

**5'CAGE (cap analysis of gene expression)** involves RNA extraction of five ends of capped transcripts, reverse transcription into DNA, PCR amplification, and sequencing to quantify the amount of each transcript.

**3'SAGE (serial analysis of gene expression)** involves extraction of unique transcript-specific tags, linking of these tags to form long serial molecules, cloning and sequencing of these serial molecules, and counting the number of tags of the corresponding transcripts for quantization.

**Massively parallel signature sequencing (MPSS)** is an open-ended platform that analyzes the level of gene expression in a sample by counting the number of individual mRNA molecules produced by each gene. Unique tags allow attachment of amplified PCR products to microbeads. After several rounds of ligation-based sequence determination using restriction endonucleases, a sequence signature is identified from each bead in parallel. The relative abundance of these signatures in a given library represents a quantitative estimate of expression of that gene.

The fundamental principles of **microarrays** and **RNA-Seq** are described in detail in the text.

---

**Fig. 1** Timeline of methods in gene expression. The figure shows a spectrum of different techniques used to measure mRNA ranging from profiling of gene expression on a limited scale to a global scale.
Microarrays function on the principle of complementary hybridization between nucleic acids (A → T and G → C) and take advantage of the knowledge of the human genome sequence [1]. DNA sequences of varying lengths representing all known genes, and even putative genes are spotted onto a solid support (eg, glass, metal, nitrocellulose, beads). A typical high-density microarray contains sequences complementary to thousands of gene sequences (probes), each immobilized to a specific spatial coordinate on the microarray surface. The RNA is extracted from tissues or cells of interest and labelled with fluorescent tags or radioactivity. The labelled RNA hybridizes only to the cDNA sequences on the array, and the signal is proportional to the abundance of the RNA in the sample. This signal is detected using autoradiography, chemiluminescence, or fluorescent scanning. A kinetic analysis allows gene expression levels to be measured by their positions on the microarray and level of hybridization (measured by signal intensity) to be detected for each probe. For data analysis, signal intensity of each probe is compared between the experimental groups to determine whether the specific mRNA of a gene in a group is upregulated, downregulated, or unaffected compared with the other group. Although recent methodologic developments have significantly reduced the technical problems of microarrays, they are still hampered by the semiquantitative nature of the measures and the fact that only currently known genes or splice variants can be measured.

The completion of the Human Genome Project, together with advances in sequencing technologies have directed the emergence of a panel of revolutionary sequencing technologies termed next-generation sequencing (NGS). Three NGS platforms currently dominate the market: SOLiD (Applied Biosystems, Foster City, CA), Genome Analyzer (Illumina, San Diego, CA) and 454 GS FLX (Roche, Basel, Switzerland), with more coming in the near future. These technologies allow generation of three to four magnitudes more sequence in a cost-effective manner than the conventional Sanger sequencing method. The fundamental nature of these systems is the miniaturization of single-molecule DNA sequencing reactions, allowing optimal spatial arrangement of each reaction and an efficient scanning for millions of individual sequences on a standard glass slide [2].

NGS has already proven successful in de novo sequencing of genomes, including the giant panda and the sequencing of total cDNA for transcriptome studies, a method known as RNA-Seq. The key advantages of RNA-Seq are the combined analysis of accurate, quantitative measurement of gene expression; unbiased discovery of novel transcribed regions; and global assessment of alternative splice sites in the genome, all in a single experiment. In RNA-Seq, a population of long RNA is converted to a library of cDNA fragments with adaptor sequences attached to one or both ends. Depending on the platform, each cDNA molecule with or without amplification is sequenced in a high-throughput manner to obtain short sequences of 30 to 400 bp. Following sequencing, the reads are typically aligned with a reference genome or transcriptome or assembled de novo to generate a base-resolution expression map for each gene at the transcriptional structure level and/or expression level. One major advantage of RNA-Seq over microarrays, especially for psychiatric disorders, in which smaller differences in gene expression are expected between disease and non-disease tissue, is that because the technique is quantitative, RNA-Seq sequences every single transcript so that quantification is not confounded by the intermediate step of hybridization, as for microarrays. The wide dynamic range of RNA-Seq allows robust capture of low expressed transcripts and makes comparisons of the transcriptome across different tissues without technical considerations such as normalization possible. Several challenges of RNA-Seq include the huge amount of data and bioinformatic analysis, library preparation biases, and other technical issues (eg, deep sequencing requirements for enough coverage of certain low expressed transcripts and low-quality reads and errors in image analysis). Despite these limitations, with the surfacing of new projects such as the 1,000 Genomes Project (http://www.1000genomes.org) and the reduction of sequencing costs, it is expected that RNA-Seq will soon surpass microarrays as the gold standard for comprehensive surveying of transcriptomes.

Choice of Target Tissues for Gene Expression Studies

To obtain meaningful results from gene expression experiments for MD research, one has to carefully consider the target tissue. Although brain tissue would be the optimal choice, its use in MD transcriptome experiments is challenging. Postmortem samples can retain their RNA quality and intact histologic architecture with careful processing but may be affected by gene expression changes accompanying death. In addition, phenotype information obtained through psychological autopsies can be confounded by its retrospective nature. This is why many researchers have investigated MD-related gene expression changes in peripheral tissue, most often peripheral blood.

Postmortem Human Brain Tissue

Gene expression patterns are likely to undergo recognizable changes in specific regions of the brain to initiate, sustain,
and/or modify the altered biological states that accompany behavioral phenotypes, thereby providing an opportunity to characterize the basis of mental disorders [3].

High-quality mRNA is a prerequisite for all molecular methods of mRNA profiling. Several groups have published detailed guidelines to assist brain banks and researchers in the processing and freezing of postmortem brains to ensure high-quality RNA [4]. Some of the factors influencing RNA quality in postmortem tissue are listed below, including pH, temperature, and length of the agonal state. Studies have indicated that below the critical pH threshold of about 6.8, transcriptional changes in stress response, apoptosis, and inflammation genes are accelerated [5]. The length of the agonal state has been shown to affect transcription, but it is still unclear to what extent neurons in different layers of the brain exhibit variable vulnerabilities and if apoptosis and RNA degradation occur at the same rates during the agonal period.

Another important factor is the selection of the brain region for analysis. Pierce and Small [6] suggested the use of brain imaging approaches to select brain regions for microarray experiments. Many brain structures have been implicated in the pathophysiology of psychiatric disorders. However, the available data point to dysregulations that affect brain circuits that involve several brain regions as opposed to single brain regions. Changes of expression in one area may only be disease relevant when accompanied by changes in other structures in the implicated circuit. This circuit-based approach, however, poses novel problems for the already complicated data analysis in expression microarray studies. In addition, smaller but relevant changes in a subpopulation of cells may be diluted and thus not recognized if a whole region is being analyzed. A combination of laser capture microscopy (LCM) and mRNA amplification techniques [7] allows the comparison of expression changes in single cells.

In addition to these technical considerations, it is important to carefully match cases and controls for a series of factors, including age, gender, ethnicity, agonal state, medications, postmortem interval, laterality of the brain, and time to processing [8].

Whole Blood, Peripheral Blood Mononuclear Cells, and Lymphocyte Cell Lines

The main reason for using peripheral blood as a target tissue to pursue transcriptomic research in MD is that blood is readily accessible. In addition, peripheral blood cells may in fact serve as surrogate markers for some of the disease processes in MD or help characterize disease state even though they are not likely the cell type causally involved in the cognitive symptoms of MD. Peripheral blood cells share more than 80% of the transcriptome with nine tissues: brain, colon, heart, kidney, liver, lung, prostate, spleen, and stomach [9], and the expression levels of many classes of biological processes have been shown to be comparable between whole blood and prefrontal cortex [10]. Indeed there is considerable communication between the immune system and the central nervous system (CNS). Many cytokine receptors have been located within the CNS, and interleukin-2 mRNA and T-cell receptors have been specifically detected in neurons [11]. Lymphocytes also express several neurotransmitter and hormone receptors, including dopamine, cholinergic, and serotonergic receptors and glucocorticoid and mineralocorticoid receptors and their chaperones [12]. Lymphocytes are directly influenced by glucocorticoids and catecholamines, and these two systems are perturbed in MD. Several studies have reported abnormalities in the immune system of psychiatric patients [12]. Studying lymphocytes in psychiatric disorders thus may yield information on disease-specific immune changes, and changes in lymphocytic immune function may serve as markers of disease progression. In addition, some receptor systems may show similar abnormalities in lymphocytes and the brain. CNS glucocorticoid receptor resistance and its resolution with antidepressant treatment is one of the most consistent biological findings in MD [13]. Steroid resistance also has been reported for the activation of T cells and monocytes in MD and bipolar disorder, suggesting comparable glucocorticoid receptor impairment in immune and CNS cells. In addition, genetic polymorphisms may similarly affect the function of molecules that are expressed in both lymphocytes and the brain. Binder et al. [14] reported that polymorphisms in FKBP5, a glucocorticoid receptor–regulating co-chaperone of hsp90, are associated with increased lymphocytic levels of FKBP5 protein, as well as an altered response of the stress hormone system, suggesting that the functional effects of these polymorphisms were not limited to immune cells, but also affected CNS function.

Transcriptional profiles in peripheral blood are highly sensitive to the collection method and other handling procedures. Three options are commonly used for transcriptional profiling of peripheral blood cells. The first is to use whole blood. This can be stabilized at the time of blood draw against RNA degradation and further transcriptional activation using proprietary reagents (eg, PAXgene RNA tubes [Qiagen, Venlo, The Netherlands] and Tempus blood RNA tubes [Applied Biosystems, Foster City, CA]) [15]. The advantage of investigating mRNA profiles stabilized at the time of blood draw may be counteracted by the fact that whole blood consists of a multitude of different cell types that may be present in varying ratios in diseased compared with control individuals and may consequently result in a heterogeneous cell mixture. Variability in the blood transcriptome may then indicate differences in cellular composition.
rather than the underlying disease processes. Furthermore, reticulocytes present in whole blood still have high levels of hemoglobin mRNA; this represents about 70% of the mRNA in whole blood. Globin mRNA has been shown to subdue hemoglobin mRNA; this represents about 70% of the mRNA present in whole blood. Therefore, studies of gene expression must take this into account [16].

Isolation of specific cell subtypes from whole blood such as peripheral blood monocytes, or even more specific subgroups such as CD4+ or CD8+ T cells, requires additional cell separation and purification steps. These have been shown to alter gene expression by inducing several cell-stress–related genes due to prolonged handling or by activating certain receptor-specific pathways if subtypes are selected using antibodies against certain surface receptors [17]. The third option is to use lymphoblastoid cell lines. Although these have been shown to be a good representation of the in vivo state [18], expression patterns of specific genes may be affected by the Epstein-Barr virus infection that is necessary for their transformation [19]. Lymphoblastoid cell lines may also exhibit extreme clonality (ie, a situation in which most cells in a culture derive from the same single-cell ancestor) with random patterns of monoclonal expression in single clones [20].

Although the use of a single cell type reduces the range of factors influencing gene expression, thus increasing the power for genetic investigations [18, 21], expression profiles may be confounded by changes in gene expression due to handling and transformation. In addition, the relatively complex procedures necessary for isolating single cell types are often impractical for large cohorts. Therefore, in practice, many studies rely on whole blood RNA collection tubes that can be easily used for data collection in large cohorts.

**Animal Brain Tissue**

Animal tissue is often the only realistic option as a tissue source for examining brain-related gene expression changes. In animals, postmortem delay is much shorter and can be held constant for all experimental groups. Gene expression studies in inbred animal strains can identify gene expression changes in a homogeneous genetic background, with the signal not masked by the noise generated from the variable genetic background present in human studies [22•]. Furthermore, several inducible gene expression systems have been developed in transgenic animals that allow expression of certain genes of interest in distinct brain regions to be turned on and off [23]. These animals represent powerful tools that enable detailed studies of the impact of individual genes on gene expression.

Optimal animal models for major depression, however, have not been developed yet, undoubtedly at least partly due to the intrinsically human nature of these complex behavioral phenotypes. One approach has been to focus on certain behavioral or endocrinologic dimensions of major depression that can be modelled in animals but do not necessarily represent the complexity of the disorder in humans. In addition, as described for human postmortem studies, neurons within a given brain region exhibit a very heterogeneous expression of neurotransmitters, receptors, and connections to other brain regions, likely leading to differential alterations of gene expression and modifications in neighboring neurons after exposure to the same stimulus. As for the human brain, cell type–specific dissection may be required [24].

Overall, there is no optimal tissue for examining gene expression changes related to MD, and we must weigh the advantages and disadvantages of each option for a specific research question.

The National Institutes of Health recently proposed an ambitious Genotype-Tissue Expression project, a database that will include expression analysis from 30 different tissues in 1,000 samples. In addition, the National Center for Biotechnology Information has initiated the Gene Expression Omnibus, a gene expression/molecular abundance repository (http://www.ncbi.nlm.nih.gov/geo/index.cgi) supporting high-quality data submissions from research groups worldwide. This curated online resource for gene expression allows data browsing, query, and retrieval in gene expression datasets from human and experimental animals, different tissue types, and different diseases, as well as physiologic states.

**Expression Array Studies in Major Depression**

**Transcriptional Profiling in Postmortem Brain Tissue**

Large variability exists in the type of brain regions investigated in postmortem gene expression studies for MD. The investigated brain regions include the amygdala, anterior cingulate cortex [25-27••], prefrontal and orbitofrontal cortex regions [28-30], and hippocampus and hypothalamus [31, 32], all of which have been implicated in the pathophysiology of MD through animal and brain imaging studies. Transcriptional profiles of different brain regions show substantial differences [27••, 29], making comparisons between profiles derived from various brain regions difficult. Even if the same regions are chosen, the proportion of neurons and glia that make up the final cells for RNA extraction remains mostly undetermined, and this may underlie some of the conflicting results from MD gene expression studies. A possible alternative is LCM, as described previously, which allows selection of specific cell types for RNA extraction. Wang et al. [33] used LCM to analyze mRNA from neurons in the paraventricular nucleus of the hypothalamus in postmortem tissue from patients with MD compared with that of controls. With a qPCR candidate
| Study                   | Disorder                          | Source of samples                                                                 | Brain region                                         | RNA analysis                                                                 | Perturbed pathway                                           |
|------------------------|-----------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------|
| Sibille et al. [27]**   | Major depression                  | Allegheny County Medical Examiner’s Office (Pittsburgh, PA)                        | Amygdala and anterior cingulate cortex               | Affymetrix GeneChip Human Genome U133 Plus 2.0 Array* > 50,000 probesets     | Oligodendrocyte structure and function                      |
| Sequeira et al. [29]    | Major depression and suicide      | Quebec Suicide Brain Bank                                                          | 17 cortical and subcortical brain regions            | Affymetrix GeneChip Human Genome U133 Plus 2.0 Array* > 45,000 probesets    | Synaptic neurotransmission and intracellular signalling     |
| Kleman et al. [46]      | Major depression and suicide      | Quebec Suicide Brain Bank                                                          | Prefrontal cortex (areas 44, 45, 46, and 47)        | Affymetrix GeneChip Human Genome U133 Plus 2.0 Array* > 45,000 probesets    | ATP biosynthesis and GABAergic neurotransmission            |
| Tochigi et al. [30]     | Major depression                  | Stanley Foundation Brain Collection                                                 | Prefrontal cortex (area 10)                         | Affymetrix HGU95A microarrays* > 12,000 probesets                            | FGFRI, NCAM1, and CAMK2A; inhibition of cell proliferation  |
| Wang et al. [33]        | Major depression                  | Netherlands Brain Bank                                                             | Hypothalamus and supraoptic nucleus                 | qPCR candidate genes                                                         | Upregulation of HPA axis–activating genes and downregulation of HPA axis–inhibiting genes |
| Kang et al. [28]        | Major depression                  | County coroner’s office in Cleveland, OH                                            | Prefrontal cortex (area 9)                          | Agilent Human 1A Oligo Microarray* > 20,000 probesets                        | Stresscopin and forkhead box D3                             |
| Sequeira et al. [26]    | Major depression and suicide      | Quebec Suicide Brain Bank                                                          | Hippocampus and amygdala, anterior and posterior cingulate gyrus (areas 24 and 29) | Affymetrix GeneChip Human Genome U133 Plus 2.0 Array* > 45,000 probesets    | GABAergic neurotransmission                                 |
| Sequeira et al. [47]    | Major depression and suicide      | Quebec Suicide Brain Bank                                                          | Orbital cortex, prefrontal cortex, and motor cortex (areas 11, 8/9, and 4) | Affymetrix GeneChip Human Genome U133 Plus 2.0 Array* > 45,000 probesets    | SSAT                                                        |
| Aston et al. [34]       | Major depression                  | Stanley Foundation Brain Collection                                                 | Temporal cortex (area 21)                           | Affymetrix HGU95A microarrays* > 12,000 probesets                            | Oligodendrocyte function                                   |
| Choudary et al. [25]    | Major depression                  | Brain Donor Program at the University of California, Irvine                        | Anterior cingulate cortex and dorsolateral prefrontal cortex (areas 24, 9, and 46) | Affymetrix HGU95A microarrays* > 12,000 probesets                            | Glutamatergic and GABAergic signal transmission             |
| Iwamoto et al. [48]     | Bipolar disorder, schizophrenia, and major depression | Stanley Foundation Brain Collection                                                 | Prefrontal cortex (area 10)                         | Affymetrix HGU95A microarrays* > 12,000 probesets                            | Genes of transcription and translation upregulated; LIM upregulated |
| Evans et al. [49]       | Major depression                  | Brain Donor Program at the University of California, Irvine                        | Dorsolateral prefrontal cortex (area 9)             | Affymetrix HGU95A microarrays* > 12,000 probesets                            | Fibroblast growth factor system                            |

*Santa Clara, CA
*Palo Alto, CA

ATP adenosine triphosphate, GABA γ-aminobutyric acid, HPA hypothalamic-pituitary-adrenal, qPCR quantitative polymerase chain reaction
gene approach, they observed an upregulation of genes activating the hypothalamus-pituitary-adrenal axis (including the corticotropin-releasing hormone and its receptor [CRHR1] and NR3C2 encoding the mineralocorticoid receptor) and downregulation of inhibiting genes (eg, androgen receptor). This was specific to neurons in the paraventricular nucleus and not observed in neurons of the supraoptic nucleus, underlining the importance of cell and region specificity in these analyses.

Genome-wide approaches, including transcriptomics, using microarrays carry the risk of false-positive associations due to the high number of performed tests. To reduce the number of reported false-positive associations, Sibille et al. [27••] used data from postmortem tissue, as well as an animal model. The authors reported an mRNA signature derived from the amygdala of depressed patients that was validated in an animal model of unpredictable chronic mild stress. In both approaches, genes implicated in oligodendrocyte structure and function were downregulated, whereas genes associated with neuronal enrichment were upregulated. This molecular signature was reversed in the stress model by antidepressive treatment. Alterations in oligodendroglial abnormalities were also shown in the temporal cortex of depressed individuals by Aston et al. [34].

Several other studies investigated gene expression changes in postmortem tissue of patients with MD, with or without suicide (Table 1). The most consistent findings were differences in expression of genes associated with glutamatergic and γ-aminobutyric acid–ergic function [25, 26, 29, 35].

### Transcriptional Profiling With RNA From Peripheral Blood Cells

To our knowledge, only one microarray study has investigated depression using RNA from peripheral white blood cells at a genome-wide level. Segman and colleagues [36] found gene expression signatures that could differentiate between women prone to postpartum depression. These differential signatures were characterized by differences in immune activation and decreased transcriptional engagement in cell proliferation, DNA replication, and repair processes. All other studies have analyzed candidate genes using qPCR methods, the results of which often have been inconsistent or could not be replicated by other groups (Table 2).

For example, Iga et al. [37] observed an increase in vascular endothelial cell growth factor mRNA in peripheral leukocytes with MD that was reversed after psychopharmacologic treatment, but this finding could not be replicated at the protein level [38]. Serotonin transporter (5-HTT) mRNA was shown to be increased in patients with MD in two reports [39, 40] but reduced in another [41].

### Transcriptional Profiling in Animal Models of Major Depression

Several different animal models for depression have been investigated using microarrays, including animals subjected to chronic stress or comparisons of behaviorally different inbred rodent lines or transgenic animals. However, no

---

**Table 2** Studies analyzing RNA from peripheral blood cells

| Study | Disorder | RNA source | RNA analysis | Perturbed pathway |
|-------|----------|------------|--------------|------------------|
| Segman et al. [36] | Postpartum depression | PBMCs | Affymetrix Human Exon 1.0b | Reduced transcription and distinct immune activation |
| Fujimoto et al. [50] | Major depression | Whole blood (QIAamp RNAb) | qPCR candidate genes | Reduced glyoxalase-1 mRNA |
| Otsuki et al. [51] | Major depression | Whole blood (QIAamp RNAb) | qPCR candidate genes | Reduced GDNF, ARTN, and neurotrophin-3 mRNAs |
| Iga et al. [52] | Major depression | Whole blood (PAXgeneb) | qPCR candidate genes | Increased CREB and HDAC5 mRNAs |
| Iga et al. [37] | Major depression | Whole blood (PAXgeneb) | qPCR candidate genes | Increased VEGF mRNA |
| Matsubara et al. [53] | Major depression | Whole blood (QIAamp RNAb) | qPCR candidate genes | Reduced GRα mRNA |
| Iga et al. [54] | Major depression | Whole blood (PAXgeneb) | qPCR candidate genes | Reduced LIM (PDLIM5) mRNA |
| Tsao et al. [40] | Major depression | PBMCs | qPCR candidate genes | Increased 5-HTT mRNA |
| Iga et al. [39] | Major depression | Whole blood (PAXgeneb) | qPCR candidate genes | Increased 5-HTT mRNA |
| Lima et al. [55] | Major depression | PBMCs | qPCR candidate genes | Reduced 5-HTT mRNA |

---

*a Santa Clara, CA

*b Qiagen, Venlo, The Netherlands

5-HTT serotonin transporter, CREB cyclic adenosine monophosphate response element-binding protein, GDNF glial cell line–derived neurotrophic factor, PBMC peripheral blood mononuclear cell, qPCR quantitative polymerase chain reaction, VEGF vascular endothelial cell growth factor.
consistent results have emerged from these studies [23, 42-44]. This may be due to inherent differences in the stress paradigms, animal strains, and brain-region specific alterations. For example, Surget et al. [45] showed specific transcriptome changes in different brain regions using the unpredictable chronic mild stress paradigm, a model of depression based on socioenvironmental stressors. Chronic administration of two pharmacologically completely different (putative) antidepressant drugs (fluoxetine and CRHR1 antagonist) reversed the behavioral effects and gene expression changes [45].

Convergent Functional Genomics

Each genome-wide molecular genetic approach bears a high risk of false-positive associations. The combination of results from several platforms to generate convergent evidence may decrease the number of false-positive hits. For example, Le-Niculescu et al. [22•] combined whole-genome gene expression data from the whole blood of bipolar patients with gene expression from the blood and brain of a pharmacologic murine model of bipolar disorder, as well as merged results from published genetic association and linkage studies and published human postmortem brain data. The authors identified five genes involved in myelination and six genes involved in growth factor signaling to show regulation and associations on all required levels. Although this specific approach has limitations, including the choice of the animal model (valproate vs methamphetamine administration), the use of convergent evidence may be a way in expression research in psychiatric disorders to identify new candidate genes.

Conclusions

Overall, the dramatic technical advances in methods to measure gene expression on a genome-wide level thus far have not been paralleled by breakthrough discoveries in MD using hypothesis-free approaches. This is due in part to technical problems. Microarrays are only semiquantitative, and their dynamic range may not be sufficiently sensitive to detect relatively subtle gene expression differences in psychiatric disorders. This problem may be solved by the use of next-generation sequencing. In addition, access to human brain tissue is difficult and only possible postmortem. Furthermore, it is still not clear whether it is sufficient to investigate changes within a single brain region or whether concerted changes in circuits have to be analyzed. Cell type–specific dissections within a region are likely necessary, but here again we lack the knowledge as to exactly which cells in which region to select. Gene expression changes in whole blood–derived mRNA can be used as disease state or treatment response markers, but they may not uncover major candidates directly involved in the pathomechanism of MD. No single animal model for major depression can claim full validity for the human condition. In addition, MD itself is mostly a biologically and genetically heterogeneous disorder. Studies relying on case-control associations without further biological or genetic stratification may never lead to consistent findings. Adding risk genotypes and endophenotypes may help select more homogeneous patient samples, which may increase the chances of finding consistent gene expression profiles for this disorder.

A next generation of gene expression experiments using biological phenotyping of patients, convergent evidence from animal models, brain-circuit related data analysis, and next-generation sequencing will be needed to make substantial progress in gene expression studies in MD.

Acknowledgments

Dr. Binder receives grant support from the National Institute of Mental Health and the Doris Duke Foundation.

Disclosure

Dr. Binder receives grant support from PharmaNeuroBoost. No other potential conflicts of interest relevant to this article were reported.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance,
•• Of major importance

1. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467–470.
2. Wilhelm BT, Landry JR: RNA-Seq–quantitative measurement of expression through massively parallel RNA-sequencing. Methods 2009, 48:249–257.
3. Bunney WE, Bunney BG, Vawter MP, et al.: Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. Am J Psychiatry 2003, 160:657–666.
4. Bell JE, Alafuzoff I, Al-Sarraj S, et al.: Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol 2008, 115:497–507.
5. Li IZ, Vawter MP, Walsh DM, et al.: Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 2004, 13:609–616.
6. Pierce A, Small SA: Combining brain imaging with microarray: isolating molecules underlying the physiologic disorders of the brain. Neurochem Res 2004, 29:1145–1152.
7. Ginsberg SD: RNA amplification strategies for small sample populations. Methods 2005, 37:229–237.
8. Hynd MR, Lewohl JM, Scott HL, Dodd PR: Biochemical and molecular studies using human autopsy brain tissue. J Neurochem 2003, 85:543–562.
9. Liew CC, Ma J, Tang HC, et al.: The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006, 147:126–132.
10. Sullivan PF, Fan C, Perou CM: Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006, 141:261–268.
11. Shimojo M, Imai Y, Nakajima K, et al.: Interleukin-2 enhances the viability of primary cultured rat neocortical neurons. Neurosci Lett 1993, 151:170–173.
12. Gladkevich A, Kauffman HF, Korf J: Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:559–576.
13. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49:391–404.
14. Binder EB, Salyakina D, Lichtner P, et al.: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36:1319–1325.
15. Asare AL, Kolchinsky SA, Gao Z, et al.: Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation. BMC Genomics 2009, 9:474.
16. Raghavachari N, Xu X, Munson PJ, Gladwin MT: Characterization of whole blood gene expression profiles as a sequel to globin mRNA reduction in patients with sickle cell disease. PLoS One 2009, 4:e6484.
17. Whitney AR, Diehn M, Popper SJ, et al.: Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 2003, 100:1896–1901.
18. Dermitzakis ET, Stranger BE: Genetic variation in human gene expression. Mamm Genome 2006, 17:503–508.
19. Liu J, Walter E, Stenger D, Thach D: Effects of globin mRNA reduction methods on gene expression profiles from whole blood. J Mol Diagn 2006, 8:551–558.
20. Plagnol V, Uz E, Wallace C, et al.: Extreme clonality in lymphoblastoid cell lines with implications for allele specific expression analyses. PLoS One 2008, 3:e2966.
21. Goring HH, Curran JE, Johnson MP, et al.: Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat Genet 2007, 39:1208–1216.
22. • Le-Niculescu H, Kurian SM, Yehyawi N, et al.: Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009, 14:156–174. This article describes the use of convergent evidence in gene expression studies.
23. Deussing JM, Kuhne C, Putz B, et al.: Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity. J Cereb Blood Flow Metab 2007, 27:1476–1495.
24. Simunovic F, Yi M, Wang Y, et al.: Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain 2009, 132:1795–1809.
25. Choudary PV, Molnar M, Evans SJ, et al.: Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005, 102:15653–15658.
26. Sequeira A, Klempan T, Canetti L, et al.: Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007, 12:640–655.
27. • Sibille E, Wang Y, Joeyen-Waldorf J, et al.: A molecular signature of depression in the amygdala. Am J Psychiatry 2009, 166:1011–1024. This article used convergent evidence from human postmortem and animal model gene expression studies.
28. Kang HJ, Adams DH, Simen A, et al.: Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci 2007, 27:13329–13340.
29. Sequeira A, Mamdani F, Ernst C, et al.: Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009, 4:e6585.
30. Tochigi M, Iwamoto K, Bundo M, et al.: Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res 2008, 60:184–191.
31. Bremner JD, Narayan M, Anderson ER, et al.: Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115–118.
32. Raadsheer FC, Hoogendijk WJ, Stam FC, et al.: Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994, 60:436–444.
33. Wang SS, Kamphuis W, Huitinga I, et al.: Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 2008, 13:786–799.
34. Aston C, Jiang L, Sokolov BP: Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 2005, 10:309–322.
35. Klempner TA, Sequeira A, Canetti L, et al.: Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 2009, 14:175–189.
36. Segman RH, Goltser-Dubner T, Weiner I, et al.: Blood mononuclear cell gene expression signature of postpartum depression. Mol Psychiatry 2010, 15:93–100.
37. Iga J, Ueno S, Yamauchi K, et al.: Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:658–663.
38. Ventriglia M, Zanardini R, Pedrini L, et al.: VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:146–149.
39. Iga J, Ueno S, Yamauchi K, et al.: Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett 2009, 458:229–233.
40. Tsao CW, Lin YS, Chen CC, et al.: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:899–905.
41. Lima L, Urbina M: Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol Neurobiol 2002, 22:797–804.
42. Joo Y, Choi KM, Lee YH, et al.: Chronic immobilization stress induces anxiety- and depression-like behaviors and decreases transthyretin in the mouse cortex. Neurosci Lett 2009, 461:121–125.
43. Orsetti M, Di Brisco F, Canonico PL, et al.: Gene regulation in the substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Eur J Neurosci 2005, 28:1259–1265.
44. Pearson KA, Stephen A, Beck SG, Valentino RJ: Identifying genes in monoamine nuclei that may determine stress vulnerability and depressive behavior in Wistar-Kyoto rats. Neuropsychopharmacology 2006, 31:2449–2461.
45. Surget A, Wang Y, Leman S, et al.: Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009, 34:1363–1380.
46. Klempan TA, Ernst C, Deleva V, et al.: Characterization of QKI gene expression, genetics, and epigenetics in suicide victims with major depressive disorder. Biol Psychiatry 2009, 66:824–831.
47. Sequeira A, Gwadry FG, Ffrench-Mullen JM, et al.: Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 2006, 63:35–48.
48. Iwamoto K, Kakiuchi C, Bundo M, et al.: Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004, 9:406–416.
49. Evans SJ, Choudary PV, Neal CR, et al.: Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 2004, 101:15506–15511.
50. Fujimoto M, Uchida S, Watanuki T, et al.: Reduced expression of glyoxalase-1 mRNA in mood disorder patients. Neurosci Lett 2008, 438:196–199.
51. Otsuki K, Uchida S, Watanuki T, et al.: Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 2008, 42:1145–1153.
52. Iga J, Ueno S, Yamauchi K, et al.: Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:628–632.
53. Matsubara T, Funato H, Kobayashi A, et al.: Reduced glucocorticoid receptor alpha expression in mood disorder patients and first-degree relatives. Biol Psychiatry 2006, 59:689–695.
54. Iga J, Ueno S, Yamauchi K, et al.: Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett 2006, 400:203–207.
55. Lima L, Mata S, Urbina M: Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression. Neuroimmunomodulation 2005, 12:299–306.